[ Inside the business ]

GEHC stock analysis

GEHC · Ge Healthcare Technologies Inc.

X-ray apparatus and tubes and related irradiation apparatus. Growing 7%. Keeps 13¢ of every dollar.

Watch: a leadership change.

The future, in 7 questions

Priced in: 0.7× sales in 5 yrs. Evidence: backlog covers it · sales +7% · 13¢ profit/$1.

01 What's priced in?0.7× sales in 5 yrs
Sales now$21.6B
Needed in 5 yrs$14.7B
Backlog$16.1B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +7%, steady
No customer over 10%
Backlog $16.1B · 0.7× salesPrepaid $3.1BSales +7%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 13¢ per $1
'21'22'23'24'2513¢
Before running costs: 39% → 40%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +0.0%/yrDebt $10B
07 What could break it?Nothing flagged

✓ All clear

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +7%, +6%, then +7% vs. a year ago. A leadership change was filed on Nov 5.

What could go wrong

Steadier than most.

It has moved 0.6× the market. Debt is heavy.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

66% Product.

Product 66% · Service 34%

Where each dollar goes

13¢ profit.

60¢ to make what it sells, 27¢ on research and overhead, 13¢ left over. Revenue $21.6B in the last 12 months.

Its market

0.6× the economy.

The government expects its industry, navigational, measuring, electromedical, and control instruments manufacturing, to grow 1.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

5 of 5 years.

Returns beat its 7.4% cost of capital in 5 of the last 5 years. Gross margin went from 41% to 40%.

Future bets

6% on research.

$1.3B a year on R&D. $526M on equipment and buildings.

All figures from Ge Healthcare Technologies Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.